Michael Becich
CEO

Cache DNA develops next-generation biopreservation technologies to support breakthroughs in the life sciences. The company focuses on storing biomolecules at unprecedented scales, moving beyond traditional freezer storage methods. This advanced preservation supports high-quality biospecimens necessary for clinical research, assay development, and personalized therapies.
Raised to date
$7.2MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.


CEO
Current methods for storing biomolecules often require specialized conditions, such as ultra-low temperatures, leading to high energy consumption and complex logistical challenges. These storage requirements increase operational costs and limit the scalability of biobanks and research facilities.
Cache DNA is developing a novel "wet operating system" for biomolecule storage and retrieval, utilizing scalable nucleic acid storage techniques to preserve biological data at room temperature. Their technology employs barcoded microcapsules and deconstructable glassy polymer networks to encapsulate and protect biomolecules, enabling long-term preservation without the need for energy-intensive cooling. This approach facilitates the indefinite retention of both digital and biological information, addressing the challenge of data loss and reducing the environmental impact of biobanking. The system allows for efficient retrieval of specific biomolecules, ensuring data integrity and accessibility for downstream applications.
The primary target audience includes biobanks, pharmaceutical companies, research institutions, and diagnostic labs seeking scalable, cost-effective, and sustainable solutions for biomolecule storage.